logo
episode-header-image
Mar 2023
8 m

Special Encore: U.S. Pharmaceuticals - T...

MORGAN STANLEY
About this episode
Original Release on February 6th, 2023: As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. 
Up next
Yesterday
The Structural Forces Moving Capital
Our Strategist Michelle Weaver talks to Michael Zezas and Jessica Alsford, Co-Directors of the Morgan Stanley Institute, about how AI, energy resilience and industrial policy are changing investment decisions.Read more insights from Morgan Stanley.----- Transcript -----Michelle W ... Show More
8m 40s
Jul 30
Blind Spots in the AI Infrastructure Selloff
Our Global Head of Thematic and Sustainability Research Stephen Byrd explains why the recent AI infrastructure selloff may reflect technical pressures, not weakening fundamentals.Read more insights from Morgan Stanley.----- Transcript -----Stephen Byrd: Welcome to Thoughts on the ... Show More
4m 8s
Jul 29
The Oil Market’s Billion-Barrel Problem
How much runway does the world’s energy market still have? Our Head of Commodity Research Martijn Rats joins our Global Head of Fixed Income Research Andrew Sheets to explain what’s causing pressure beyond renewed tensions in the Middle East.Read more insights from Morgan Stanley ... Show More
13m 7s
Recommended Episodes
Jan 2022
Starting a company to fight rare disease
Mapping the human genome led to big advances in diagnosing rare disease. But diagnosis is only the first step in dealing with an illness. So what do you do if your child is found to have a condition that has no treatment? We hear from Michelle Teng, a mother who co-founded a biot ... Show More
17m 28s
May 2019
a16z Podcast: The Economics of Expensive Medicines
<p>with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)</p> <p>The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ... Show More
33m 22s
Oct 2021
Gene Silencing Treatments
The future is here. Gene silencing medicines - which can fine tune how our DNA works - have held promise for decades. Now hundreds of thousands of people will get them in the UK. James speaks to a surgeon whose life and career have been saved by gene-silencing drugs and to resear ... Show More
28m 1s
Jan 2024
Unlocking Gene Therapy with Gaurav Shah
<p>Are rare diseases themselves rare? Neil deGrasse Tyson and comedian Chuck Nice learn about the science of gene therapy and how it can treat and potentially cure rare diseases with Gaurav Shah, CEO, Rocket Pharma.</p><p>NOTE: StarTalk+ Patrons can listen to this entire episode ... Show More
39m 56s
Mar 2025
Gene Therapy for Hearing Loss
Interview with Oliver F. Adunka, MD, MBA, and Vinay K. Rathi, MD, MBA, authors of Gene Therapy for Hearing Loss–Will the Price be Right? Hosted by Paul C. Bryson, MD, MBA. Related Content: Gene Therapy for Hearing Loss—Will the Price be Right? 
20m 8s
Jan 2024
JP Morgan Healthcare Conference Highlights
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ... Show More
26m 16s
Nov 2021
Genetic dreams, genetic nightmares
Professor Matthew Cobb looks at how genetic engineering became big business - from the first biotech company that produced human insulin in modified bacteria in the late 1970s to the companies like Monsanto which developed and then commercialised the first GM crops in the 1990s. ... Show More
27m 29s
Listen to millions of songs and podcasts on Anghami